Indrayani Biotech Limited has formally notified BSE Limited about its Rights Issue Committee meeting scheduled for April 09, 2026. The company communicated this development on April 06, 2026, in compliance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Committee Meeting Agenda

The Rights Issue Committee will convene to consider and approve comprehensive details regarding the company's proposed partly paid-up rights issue. The committee has resolved to finalize critical parameters that will determine the structure and execution of this corporate action.

Rights Issue Parameters Under Review

The committee will determine the total number of rights equity shares to be issued to achieve the desired issue size. Additionally, several fundamental parameters will be established including the rights issue price, rights entitlement ratio, and the rights issue period.

The committee will also fix the record date to identify eligible shareholders who will be entitled to participate in the rights offering. These parameters are crucial for the successful execution of the partly paid-up rights issue.

Service Provider Appointments

Beyond setting the rights issue parameters, the committee will address operational aspects through formal appointments of essential service providers. The meeting agenda includes the appointment of monitoring agency and banker to the issue to manage fund flows and ensure compliance throughout the rights issue process.

Regulatory Compliance Framework

The announcement was made pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates listed companies to inform stock exchanges about meetings where material decisions are expected. The communication was signed by Ramya Ravi, Company Secretary and Compliance Officer, ensuring adherence to corporate governance protocols for this significant corporate action.

Indrayani Biotech Limited has announced a board meeting scheduled for April 9, 2026, to deliberate on a significant corporate restructuring proposal. The company filed a regulatory notice on April 6, 2026, informing the BSE about the upcoming board deliberations.

Board Meeting Details

The board meeting has been convened under Regulation 29 of the SEBI (LODR) Regulations, 2015, with a specific focus on evaluating a demerger proposal. The primary objective of this corporate action is to unlock shareholder value through strategic restructuring.

Demerger Proposal Overview

The proposed demerger involves separating one of the company's units into a separate entity. This corporate restructuring strategy is designed to create distinct business entities that can operate independently, potentially leading to enhanced operational efficiency and improved market valuation.

The company's board will deliberate and evaluate the various aspects of this demerger proposal during the scheduled meeting. Such corporate actions typically require comprehensive analysis of financial implications, regulatory compliance, and strategic benefits.

Trading Window Status

Indrayani Biotech Limited has confirmed that the trading window for dealing in the company's securities remains closed. This closure is in connection with the upcoming declaration of financial results and will continue until 48 hours after the results are made public.

The regulatory filing was signed by Ramya Ravi, Company Secretary and Compliance Officer, ensuring proper corporate governance and regulatory compliance in the announcement process.